Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.

<h4>Objective</h4> <p>To assess the incremental cost and costeffectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective.</p...

Description complète

Détails bibliographiques
Auteurs principaux: Dakin, H, Wordsworth, S, Rogers, C, Abangma, G, Raftery, J, Harding, S, Lotery, A, Downes, S, Chakravarthy, U, Reeves, B
Format: Journal article
Langue:English
Publié: BMJ Publishing Group 2014